Progress on serum tumor biomarkers of endometrial carcinoma

doi:10.3760/cma.j.issn.1673-422X.2014.05.014

Abstract

Abstract: Serum tumor biomarkers are significant for the early diagnosis and treatment, preoperative evaluation, prognosis prediction and relapse surveillance of endometrial carcinoma. Recently, serum CA125 and human epididymal secretory protein 4 are widely recognized as closely related with staging, metastasis and prognosis of endometrial cancer. In addition, the serum miRNAs are characterized by their features of high stability and specificity. Omics studies will be helpful for the general assessment of the initiation and progression of endometrial cancer. Insights into these two aspects will facilitate the identifications of new biomarkers with higher sensitivity and specificity for endometrial carcinoma.

Key words: Endometrial neoplasms, Tumor markers, biological, Serum

Chen Ruifang, Lu Xin. Progress on serum tumor biomarkers of endometrial carcinoma[J]. Journal of International Oncology, 2014, 41(5): 364-367.

References

［1］ Chao A, Tang YH, Lai CH, et al. Potential of an agestratified CA125 cutoff value to improve the prognostic classification of patients with endometrial cancer［J］. Gynecol Oncol, 2013, 129(3):500-504. ［2］ Nicklin J, Janda M, Gebski V, et al. The utility of serum CA125 in predicting extrauterine disease in apparent earlystage endometrial cancer［J］. Int J Cancer, 2012, 131(4):885-890. ［3］ Suh DH, Kim HS, Chung HH, et al. Preoperative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma［J］. Eur J Obstet Gynecol Reprod Biol, 2012, 162(2):206-210. ［4］ Yildiz A, Yetimalar H, Kasap B, et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma［J］. Eur J Obstet Gynecol Reprod Biol, 2013, 164(2):191-195. ［5］ Yu B, Xu PZ, Wang QW, et al. Clinical value of tumor specific growth factor(TSGF) and carbohydrate antigen125(CA125) in carcinoma of the endometrium［J］. J Int Med Res, 2009, 37(3):878-883. ［6］ MutzDehbalaie I, Eqle D, Fessler S, et al. HE4 is an independent prognostic marker in endometrial cancer patients［J］. Gynecol Oncol, 2012, 126(2):186-191. ［7］ Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus［J］. Gynecol Oncol, 2008, 110(2):196-201. ［8］ Angioli R, Plotti F, Capriglione S, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study［J］. Tumour Biol, 2013, 34(1):571-576. ［9］ Saarelainen SK, Peltonen N, Lehtimki T, et al. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma［J］. Am J Obstet Gynecol, 2013, 209(2):142.e1-6. ［10］ Kalogera E, Scholler N, Powless C, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer［J］. Gynecol Oncol, 2012, 124(2):270-275. ［11］ Wang LJ, Zhou H, Lu HW, et al. Prognostic value of preoperative serum high sensitivity Creactive protein in patients with endometrial cancer［J］. Zhonghua Yi Xue Za Zhi, 2011, 91(41):2927-2930. ［12］ Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and metaanalysis［J］. JAMA, 2009, 302(2):179-188. ［13］ Karahanoglu E, Adanir I, Boyraz G, et al. Preoperative serum leptin levels in patients with endometrial cancer and its correlation with prognostic variables［J］. Eur J Gynaecol Oncol, 2012, 33(3):278-280. ［14］颜春晓, 盛修贵.子宫内膜癌血管生成相关因子研究进展［J］. 国际肿瘤学杂志, 2012, 39(3):230-233. ［15］ Dobrzycka B, Terlikowski SJ, Kowalczuk O, et al. Serum levels of VEGF and VEGFC in patients with endometrial cancer［J］. Eur Cytokine Netw, 2011, 22(1):45-51. ［16］ Coenegrachts L, Schrauwen S, Van Bree R, et al. Increased expression of placental growth factor in highgrade endometrial carcinoma［J］. Oncol Rep, 2013, 29(2):413-418. ［17］ Dobrzycka B, MackowiakMatejczyk B, Kinalski M, et al. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma［J］. Gynecol Oncol, 2013, 128(3):454-460. ［18］ Fan JT, Si XH, Liao Y, et al. The diagnostic and prognostic value of serum YKL40 in endometrial cancer［J］. Arch Gynecol Obstet, 2013, 287(1):111-115. ［19］ Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL40 is a marker for detection and prognosis of endometrial cancer［J］. Gynecol Oncol, 2007, 104(2):435-442. ［20］梁静, 马本红, 张贵宇. 微RNA与子宫内膜癌［J］. 国际肿瘤学杂志, 2011, 38(11):854858. ［21］ Tan ZQ, Liu FX, Tang HL, et al. Expression and its clinical significance of hsamiR155 in serum of endometrial cancer［J］. Zhonghua Fu Chan Ke Za Zhi, 2010, 45(10):772-774. ［22］ Lee JW, Park YA, Choi JJ, et al. The expression of the miRNA200 family in endometrial carcinoma［J］. Gynecol Oncol, 2011, 120(1):56-62. ［23］ Van Gorp T, Cadron I, Vergote I. The utility of proteomics in gynecologic cancers［J］. Curr Opin Obstet Gynecol, 2011, 23(1):3-7. ［24］ DeSouza LV, Krakovska O, Darfler MM, et al. mTRAQbased quantification of potential endometrial carcinoma biomarkers from archived formalinfixed paraffinembedded tissues［J］. Proteomics, 2010, 10(17):3108-3116. ［25］ Liang H, Cheung LW, Li J, et al. Wholeexome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer［J］. Genome Res, 2012, 22(11): 2120-2129. ［26］ Altme S, Esteban FJ, StavreusEvers A, et al. Guidelines for the design, analysis and interpretation of ′omics′ data: focus on human endometrium［J］. Hum Reprod Update, 2014, 20(1):12-28. ［27］蔡彦卿. 差异蛋白质组学技术鉴定的子宫内膜癌标记蛋白［J］. 国际肿瘤学杂志, 2008, 35(6):461-463.

[1]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Li Dan, Li Ruiyao, Li Yinghan, Yu Xiuyan, Wu Xuefeng. Clinical value of serum miR-19b and miR-744-5p levels in the diagnosis of non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 83-88.
[3]	Fan Mengsi, Lu Yaping, Yan Li. Analysis of clinicopathologic features of false negative sentinel lymph nodes in patients with endometrial cancer [J]. Journal of International Oncology, 2023, 50(5): 274-279.
[4]	Xu Qiuyue, Ma Xianmei, Yue Qi. Immunotherapy for endometrial carcinoma based on molecular typing [J]. Journal of International Oncology, 2022, 49(11): 700-704.
[5]	Deng Bo'er, Kong Weimin. Epigenetic research progress of endometrial cancer [J]. Journal of International Oncology, 2021, 48(3): 184-188.
[6]	Huang Yuting, Wang Chao. Anti-tumor effect of berberine hydrochloride combined with epirubicin and cisplatin on advanced endometrial carcinoma [J]. Journal of International Oncology, 2020, 47(9): 530-534.
[7]	Wang Xue, Ji Guoxin, Ji Chao, Yang Xingsheng. Effects of metformin on prognosis of type Ⅰ endometrial carcinoma patients complicated with type 2 diabetes mellitus [J]. Journal of International Oncology, 2020, 47(7): 404-408.
[8]	Zhao Xiaoling, Kong Weimin. Current status of basic and clinical research on metformin in endometrial cancer [J]. Journal of International Oncology, 2020, 47(7): 440-443.
[9]	Zhou Luqiu, Liu Xianxi, Li Yan, Mao Xiguang. Analysis of prognostic risk factors of type Ⅰ endometrial cancer [J]. Journal of International Oncology, 2020, 47(6): 346-350.
[10]	Luo Chuncui, Yuan Chaoyan, Chen Qingfen. GOLPH3 regulates proliferation and apoptosis of endometrial carcinoma cells through PI3K/AKT/GSK3β signal [J]. Journal of International Oncology, 2020, 47(2): 65-69.
[11]	ZHANG Wan-Hua, SONG Fu-Ting. Expression and clinical significance of serum miR-139-5p in patients with ovarian cancer [J]. Journal of International Oncology, 2018, 45(2): 96-99.
[12]	LI Mei-Yan. Clinical significance of detection of HE4, OPN and uPA in the diagnosis of endometrial carcinoma [J]. Journal of International Oncology, 2017, 44(5): 351-355.
[13]	Zou Rongji, Ma Qingjiu. Research progress on body fluids microRNAs in the diagnosis of cholangiocarcinoma [J]. Journal of International Oncology, 2017, 44(4): 300-303.
[14]	Gao Wuyuan, Wang Lihua. Role of insulinlike growth factors family in endometrial cancer [J]. Journal of International Oncology, 2017, 44(10): 794-797.
[15]	Ma Wen, Cai Hongyi, Miao Guoying, Hu Yongguo, Wang Jiankai, Zhang Lijuan. Postoperative radiotherapy and postoperative chemotherapy for patients with endometrial cancer: a Meta-analysis [J]. Journal of International Oncology, 2016, 43(11): 829-834.